Adverse Effects Under Th2 Biologics (Dupilumab and Tezepelumab) in a Patient with Severe Asthma and Atopic Dermatitis

被引：1
|
作者：
Suhling, Hendrik [1 ]
Hinze, Christopher Alexander [1 ]
Welte, Tobias [1 ]
Werfel, Thomas [2 ]
Traidl, Stephan [2 ]
机构：
[1] Hannover Med Sch, Dept Resp Med & Infect Dis, Hannover, Germany
[2] Hannover Med Sch, Dept Dermatol & Allergy, Hannover, Germany
来源：
RESPIRATION | 2023年 / 102卷 / 12期
关键词：
Severe asthma; Dupilumab; Tezepelumab; Side effects;
D O I：
10.1159/000534924
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
Introduction: This is the first report of a patient with severe asthma and atopic dermatitis that developed local perioral skin infection which onset coincided with the patient's treatment with dupilumab (candida albicans) and later with tezepelumab (microscopic detection of yeast). Case Presentation: Besides moderate headache, macular exanthema was found after administration of tezepelumab, which was subsequently accompanied by a worsening of symptoms upon reexposure to the treatment. Both sensations needed multidisciplinary treatment and both antibody therapies were stopped.
引用
收藏
页码：1016 / 1019
页数：4
相关论文
共 50 条
  • [31] Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults: A pooled analysis of two phase 2 clinical trials
    Tofte, Susan J.
    Papp, Kim
    Sadick, Neil
    Bohnert, Krista
    Simpson, Eric
    Thaci, Diamant
    Bieber, Thomas
    Blauvelt, Andrew
    Sofen, Howard
    Gooderham, Melinda
    Chen, Zhen
    Gadkari, Abhijit
    Eckert, Laurent
    Graham, Neil M. H.
    Pirozzi, Gianluca
    Ardeleanu, Marius
    JOURNAL OF THE AMERICAN ASSOCIATION OF NURSE PRACTITIONERS, 2018, 30 (09): : 529 - 541
  • [32] Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2
    Cork, Michael J.
    Eckert, Laurent
    Simpson, Eric L.
    Armstrong, April
    Barbarot, Sebastien
    Puig, Luis
    Girolomoni, Giampiero
    de Bruin-Weller, Marjolein
    Wollenberg, Andreas
    Kataoka, Yoko
    Remitz, Anita
    Beissert, Stefan
    Mastey, Vera
    Ardeleanu, Marius
    Chen, Zhen
    Gadkari, Abhijit
    Chao, Jingdong
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2020, 31 (06) : 606 - 614
  • [33] Current novel approaches in systemic therapy of atopic dermatitis: specific inhibition of cutaneous Th2 polarized inflammation and itch
    Werfel, Thomas
    Biedermann, Tilo
    CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY, 2015, 15 (05) : 446 - 452
  • [34] Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab versus Dupilumab in Moderate-to-Severe Atopic Dermatitis
    Rand, Kim
    Ramos-Goni, Juan Manuel
    Akmaz, Bulent
    Sole-Feu, Laia
    Armario-Hita, Jose-Carlos
    DERMATOLOGY AND THERAPY, 2024, 14 (01) : 169 - 182
  • [35] Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab versus Dupilumab in Moderate-to-Severe Atopic Dermatitis
    Kim Rand
    Juan Manuel Ramos-Goñi
    Bülent Akmaz
    Laia Solé-Feu
    José-Carlos Armario-Hita
    Dermatology and Therapy, 2024, 14 : 169 - 182
  • [36] Coronavirus infection in an unvaccinated atopic dermatitis patient under ongoing dupilumab therapy: eczema flare-up, but moderate COVID-19 symptoms
    Anasiewicz N.
    Seeli C.
    Brüggen M.-C.
    Möhrenschlager M.
    Allergo Journal International, 2023, 32 (6) : 176 - 177
  • [37] Assessment of Patient-Reported Outcomes at 48 Months of Treatment with Dupilumab for Severe Atopic Dermatitis: A Single-Center Real-Life Experience with 126 Patients
    Barei, Francesca
    Zussino, Martina
    Tavecchio, Simona
    Angileri, Luisa
    Rizzo, Arianna
    Calzari, Paolo
    Marzano, Angelo V.
    Ferrucci, Silvia
    PHARMACEUTICALS, 2024, 17 (01)
  • [38] Dupilumab modulates specific IgE mite responses at the molecular level in severe T2-high atopic dermatitis: A real-world experience
    Gonzalez-Perez, Ruperto
    Poza-Guedes, Paloma
    Mederos-Luis, Elena
    Sanchez-Machin, Inmaculada
    FRONTIERS IN MEDICINE, 2022, 9
  • [39] Relevance of TH2 Markers in the Assessment and Therapeutic Management of Severe Allergic Asthma: A Real-Life Perspective
    Caminati, M.
    Vianello, A.
    Bianchi, Chieco F.
    Festi, G.
    Guarnieri, G.
    Marchi, M. R.
    Micheletto, C.
    Olivieri, M.
    Tognella, S.
    Guerriero, M.
    Senna, G.
    Artioli, Denise
    Bertocco, Elisabetta
    Bonazza, Lucio
    Crivellaro, Mariangiola
    De Conti, Fabio
    Dama, Annarita
    Donazzan, Giulio
    Idotta, Giuseppe
    Lombardi, Carlo
    Marino, Luigi
    Mazza, Francesco
    Nardini, Stefano
    Reccardini, Federico
    Schiappoli, Michele
    JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY, 2020, 30 (01) : 35 - 41
  • [40] Mapping atopic dermatitis and anti-IL-22 response signatures to type 2-low severe neutrophilic asthma
    Badi, Yusef Eamon
    Pavel, Ana B.
    Pavlidis, Stelios
    Riley, John H.
    Bates, Stewart
    Kermani, Nazanin Zounemat
    Knowles, Richard
    Kolmert, Johan
    Wheelock, Craig E.
    Worsley, Sally
    Uddin, Mohib
    Alving, Kjell
    Bakke, Per S.
    Behndig, Annelie
    Caruso, Massimo
    Chanez, Pascal
    Fleming, Louise J.
    Fowler, Stephen J.
    Frey, Urs
    Howarth, Peter
    Horvath, Ildiko
    Krug, Norbert
    Maitland-van der Zee, Anke H.
    Montuschi, Paolo
    Roberts, Graham
    Sanak, Marek
    Shaw, Dominick E.
    Singer, Florian
    Sterk, Peter J.
    Djukanovic, Ratko
    Dahlen, Sven-Eric
    Guo, Yi-Ke
    Chung, Kian Fan
    Guttman-Yassky, Emma
    Adcock, Ian M.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2022, 149 (01) : 89 - 101
12345